利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.018 秒)

    EGFH2 genes and gene products
    2.
    发明申请
    EGFH2 genes and gene products 失效
    EGFH2基因和基因产物

    公开(公告)号：US20080004428A1

    公开(公告)日：2008-01-03

    申请号：US11656882

    申请日：2007-01-22

    申请人： W. Kavanaugh ,  Hui Cen ,  Pauline Lee

    发明人： W. Kavanaugh ,  Hui Cen ,  Pauline Lee

    IPC分类号： C07K7/06 ,  C07K14/00

    CPC分类号： C07K14/4756 ,  A61K38/00

    摘要： This invention relates to mouse and human EGFH2, and to variants thereof and to polynucleotides encoding EGFH2. This invention also relates to therapeutic agents related to the polynucleotides and proteins.

    摘要翻译： 本发明涉及小鼠和人EGFH2及其变体，以及编码EGFH2的多核苷酸。 本发明还涉及与多核苷酸和蛋白质相关的治疗剂。

    Human FGF-23 gene and gene expression products
    5.
    发明申请
    Human FGF-23 gene and gene expression products 审中-公开
    人FGF-23基因和基因表达产物

    公开(公告)号：US20060281679A1

    公开(公告)日：2006-12-14

    申请号：US11322185

    申请日：2005-12-28

    申请人： Nobuyuki Itoh ,  W. Kavanaugh

    发明人： Nobuyuki Itoh ,  W. Kavanaugh

    IPC分类号： A61K38/18 ,  C07H21/04 ,  C12P21/06 ,  C07K14/50

    CPC分类号： C07K14/50 ,  A61K38/00 ,  A61K48/00 ,  C12N2799/026

    摘要： This invention relates to human fibroblast growth factor (hFGF-23), to cleavage products of hFGF-23, and to variants thereof and to polynucleotides encoding FGF-23. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating skin, brain and placental disease and disorders, and methods of treating conditions related to thymic function. The invention also relates to mouse fibroblast growth factor (mFGF-23), and to variants thereof and polynucleotides encoding mFGF-23.

    摘要翻译： 本发明涉及人成纤维细胞生长因子（hFGF-23），hFGF-23的切割产物及其变体和编码FGF-23的多核苷酸。 本发明还涉及与多核苷酸和蛋白质相关的诊断和治疗剂，包括探针和抗体，以及治疗皮肤，脑和胎盘疾病和病症的方法，以及治疗与胸腺功能相关的病症的方法。 本发明还涉及小鼠成纤维细胞生长因子（mFGF-23）及其变体和编码mFGF-23的多核苷酸。

    Angiogenically effective unit dose fo FGF and method of adminstering
    6.
    发明申请
    Angiogenically effective unit dose fo FGF and method of adminstering 有权
    FGF的血管生成有效单位剂量和施用方法

    公开(公告)号：US20060025343A1

    公开(公告)日：2006-02-02

    申请号：US11238936

    申请日：2005-09-29

    申请人： Martha Whitehouse ,  W. Kavanaugh

    发明人： Martha Whitehouse ,  W. Kavanaugh

    IPC分类号： A61K38/18

    CPC分类号： A61K38/1825

    摘要： The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present invention is directed to a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Typically, the angiogenically effective dose comprises 0.2 μg/kg to 36 μg/kg of an FGF of any one of SEQ ID NOS:1-3, 5, 8-10, or 12-14 or an angiogenically active fragment or mutein thereof. In yet another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF of any one of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.

    摘要翻译： 本发明具有多个方面。 特别地，一方面，本发明涉及包含0.2μg/ kg至36mug / kg重组FGF或其血管生成活性片段或突变蛋白的单位剂量。 在另一方面，本发明涉及包含血管生成有效剂量的FGF或其血管生成活性片段或突变蛋白和药学上可接受的载体的药物组合物。 通常，血管生成有效剂量包含0.2μg/ kg至36mug / kg SEQ ID NO：1-3,5,8-10或12-14中任一项的FGF或其血管生成活性片段或突变蛋白。 另一方面，本发明涉及用于治疗冠状动脉疾病的人类患者的方法，包括对需要治疗冠状动脉疾病的人类患者的至少一个冠状血管施用安全和血管生成有效剂量的 SEQ ID NO：1-3,5,8-10或12-14中任一项的重组FGF或其血管生成活性片段或突变蛋白。

    Dose of an angiogenic factor and method of administering to improve myocardial blood flow
    7.
    发明申请
    Dose of an angiogenic factor and method of administering to improve myocardial blood flow 有权

    公开(公告)号：US20060009390A1

    公开(公告)日：2006-01-12

    申请号：US11220027

    申请日：2005-09-06

    申请人： David Hung ,  Brian Annex ,  Kevin Landolfo ,  W. Kavanaugh

    发明人： David Hung ,  Brian Annex ,  Kevin Landolfo ,  W. Kavanaugh

    IPC分类号： A61K38/18

    CPC分类号： A61K38/1858 ,  A61K38/1825 ,  A61K38/1866

    摘要： The present invention has multiple aspects. In one aspect, the present invention is directed to a unit dose pharmaceutical composition comprising from about 5 ng/dose to less than 135,000 ng of an angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it is basic FGF (FGF-2). In its second aspect, the present invention is directed to a method for inducing angiogenesis, or increasing myocardial perfusion or vascular density in a patient's heart, comprising administering directly into the myocardium in an area in need, as a single injection or a series of injections, a unit dose of an angiogenic agent. It is also within the scope of the present invention that a plurality of unit dose compositions be administered directly into the myocardium at a plurality of sites in need of angiogenesis. In another aspect, the present invention is directed to a method for treating a patient for coronary artery disease, comprising administering directly into the myocardium in an area of need of angiogenesis in said patient, a unit dose (i.e., from about 5 ng to less than 135,000 ng) of an angiogenic agent. In yet another aspect, the present invention is directed to a method for treating a patient for a myocardial infarction, comprising administering directly into the myocardium in an area in need of angiogenesis in said patient, a unit dose (i.e., from about 5 ng to less than 135,000 ng) of an angiogenic agent.